The Brazilian pharmaceutical market will expand in value from $29.4 billion in 2014 to reach around $47.9 billion by 2020, representing a strong compound annual growth rate (CAGR) of 8.5%, new research indicates.
According to research and consulting firm GlobalData’s latest report, Brazil’s increasingly elderly population, which will lead to a rising incidence of chronic and lifestyle-associated diseases, as well as the country’s robust investment in health care, will be key drivers of market growth during the forecast period.
Joshua Owide, GlobalData’s director of healthcare industry dynamics, says that the Brazilian pharmaceutical industry continues to prosper, primarily thanks to the country’s economic policies and reforms, noting: “Brazil has emerged as a global manufacturing hub for pharmaceutical and biotechnology companies, with countries such as India investing heavily in the manufacturing sector after former Brazilian Health Minister, José Serra, invited investment from generic companies.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze